WAVE Life Sciences Ltd (1U5.MU)
| Previous Close | 4.48 |
| Open | 5.25 |
| Bid | 5.25 x N/A |
| Ask | 5.35 x N/A |
| Day's Range | 5.25 - 5.25 |
| 52 Week Range | 3.24 - 6.20 |
| Volume | |
| Avg. Volume | 0 |
| Market Cap | N/A |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | May 02, 2024 - May 06, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
GlobeNewswireWave Life Sciences Announces Approval of First Clinical Trial Application for RestorAATion-2 Trial of WVE-006 in Individuals with Alpha-1 Antitrypsin Deficiency (AATD)
Proof-of-mechanism data for WVE-006 in individuals with AATD remain on track for 2024CAMBRIDGE, Mass., April 30, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced the approval of its first clinical trial application (CTA) for its RestorAATion-2 clinical trial of WVE-006, the company’s first-in-class RNA editing oligonucleotide, which is being d
- GlobeNewswire
Wave Life Sciences Announces Continued Momentum in GSK Collaboration and Advancements in siRNA and RNA Editing
GSK has selected the first two programs to advance following achievement of target validation, marking transition to next phase of research collaboration; programs utilize Wave’s next generation GalNAc-siRNA format with potential for best-in-class potency and durability GSK collaboration continues to span all Wave modalities, including RNA editing, with target validation ongoing in multiple therapy areas Wave is on track to initiate a clinical trial of its wholly owned INHBE program for obesity
- GlobeNewswire
Wave Life Sciences to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in two upcoming investor conferences in April. Cantor Virtual Muscular Dystrophy Symposium Date: Wednesday, April 3, 2024Analyst-led fireside chat presentation time: 3:10 p.m.
